Trial Profile

Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lifileucel (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors Iovance Biotherapeutics; Lion Biotechnologies Inc

Most Recent Events

27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
16 Sep 2015 According to a Lion Biotechnologies media release, updated results from this trial were presented at the American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference.
16 Sep 2015 Updated results from this trial were published in a Lion Biotechnologies media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com